強
強気
強気 · 25%APUS
$2.05
シナリオ価格
$2.685
-0.044 (-1.65%)終値時点
Loading chart…
- 高値
- 2.752
- 始値
- 2.670
- 出来高加重平均価格
- 2.66
- 出来高
- 15.08K
- 時価総額
- —
- 安値
- 2.530
- 売買代金
- 40.05K
- EV/EBITDA（TTM）
- 0.00
Apimeds Pharmaceuticals US, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in developing Apitox, an intradermally administered bee venom-based toxin. It is focused on developing Apitox in the treatment of inflammatory conditions in the United States, specifically osteoarthritis and multiple sclerosis. Its subsidiary, MindWave Innovations Inc, is a provider of institutional digital asset treasury (DAT) solutions.
AI分析 of Apimeds Pharmaceuticals US Inc (APUS)
売りApimeds Pharmaceuticals US Inc is not a good buy right now due to its significant financial losses and poor technical indicators. The current price is $2.68, and the company has reported a staggering net income loss of $35,059,852 in Q1 2026. Additionally, the RSI is at 26.149, indicating that the stock is oversold, but this does not suggest a buying opportunity given the ongoing financial instability.
バリュエーション指標
Apimeds Pharmaceuticals US Inc（APUS）の現在の予想PERは0.00で、5年平均は0.00です。
Alphio AI による APUS の価格シナリオ
シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト（25 / 50 / 25）であり、保証ではありません。
イベントタイムライン
ニュース
8.510-13NewsfilterMindWave Lists NILA Token on Pionex Exchange
- 7.510-09Newsfilter
MindWave Signs Three Blockchain Agreements Across Diverse Industries
8.507-28GlobenewswireMindChain: The World's First Fully Insured Blockchain Launching Soon
- 8.507-28Newsfilter
MindWave Launches World's First Fully Insured Blockchain
8.505-06NASDAQ.COMApimeds Reaches Settlement with Inscobee, Clearing Path for Merger
APUS のよくある質問 — Alphio AI が回答
Apimeds Pharmaceuticals US, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in developing Apitox, an intradermally administered bee venom-based toxin. It is focused on developing Apitox in the treatment of inflammatory conditions in the United States, specifically osteoarthritis and multiple sclerosis. Its subsidiary, MindWave Innovations Inc, is a provider of institutional digital asset treasury (DAT) solutions. It operates in the Healthcare sector.
Apimeds Pharmaceuticals US Inc is not a good buy right now due to its significant financial losses and poor technical indicators. The current price is $2.68, and the company has reported a staggering net income loss of $35,059,852 in Q1 2026. Additionally, the RSI is at 26.149, indicating that the stock is oversold, but this does not suggest a buying opportunity given the ongoing financial instability.
コミュニティ
もっと見る ↗投稿はまだありません
登録またはログインして議論に参加関連記事
- Are You Buying NVIDIA’s Earnings or Its CEO’s Perfect Image?An Alphio analysis of NVIDIA’s share-price timeline, operating results, governance uncertainty and upcoming earnings.
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。